Suppr超能文献

利用全身磁共振成像评估1型神经纤维瘤病患者的良性肿瘤负荷。

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

作者信息

Mautner Victor-F, Asuagbor Florence A, Dombi Eva, Fünsterer Carsten, Kluwe Lan, Wenzel Ralf, Widemann Brigitte C, Friedman Jan M

机构信息

Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany.

出版信息

Neuro Oncol. 2008 Aug;10(4):593-8. doi: 10.1215/15228517-2008-011. Epub 2008 Jun 17.

Abstract

People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients with MPNSTs and 26 age- and sex-matched controls (NF1 patients who did not have MPNSTs) with detailed clinical examinations and whole-body MRI to characterize their body burden of internal benign neurofibromas. Internal plexiform neurofibromas were identified in 22 (56%) of the 39 NF1 patients studied. All six of the NF1 patients with MPNSTs under 30 years of age had neurofibromas visualized on whole-body MRI, compared to only 3 of 11 matched NF1 controls under age 30 (p < 0.05). Both the median number of plexiform neurofibromas (p < 0.05) and the median neurofibroma volume (p < 0.01) on whole-body MRI were significantly greater among MPNST patients younger than 30 years of age than among controls. No significant differences in whole-body MRI findings were observed between NF1 patients with MPNSTs and controls who were 30 years of age or older. Whole-body MRI of NF1 patients allows assessment of the burden of internal neurofibromas, most of which are not apparent on physical examination. Whole-body imaging of young NF1 patients may allow those at highest risk for developing MPNST to be identified early in life. Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop.

摘要

1型神经纤维瘤病(NF1)患者有多个良性神经纤维瘤,一生中发生恶性外周神经鞘瘤(MPNST)的风险为10%。大多数MPNST由良性丛状神经纤维瘤发展而来,因此良性肿瘤负荷可能是发生MPNST的一个风险因素。我们对13例患有MPNST的NF1患者和26例年龄及性别匹配的对照者(未患MPNST的NF1患者)进行了详细的临床检查和全身MRI检查,以确定其体内良性神经纤维瘤的负荷情况。在研究的39例NF1患者中,有22例(56%)发现了体内丛状神经纤维瘤。所有6例30岁以下患有MPNST的NF1患者在全身MRI上都能看到神经纤维瘤,而在30岁以下的11例匹配的NF1对照者中只有3例能看到(p<0.05)。30岁以下MPNST患者全身MRI上丛状神经纤维瘤的中位数(p<0.05)和神经纤维瘤体积中位数(p<0.01)均显著高于对照组。30岁及以上患有MPNST的NF1患者与对照组在全身MRI检查结果上未观察到显著差异。NF1患者的全身MRI检查可评估体内神经纤维瘤的负荷情况,其中大多数在体格检查中并不明显。对年轻NF1患者进行全身成像检查可能有助于在其生命早期识别出发生MPNST风险最高的患者。对这些高危患者进行密切监测可能有助于更早诊断并更有效地治疗发生的MPNST。

相似文献

1
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
Neuro Oncol. 2008 Aug;10(4):593-8. doi: 10.1215/15228517-2008-011. Epub 2008 Jun 17.
2
Association between benign and malignant peripheral nerve sheath tumors in NF1.
Neurology. 2005 Jul 26;65(2):205-11. doi: 10.1212/01.wnl.0000168830.79997.13.
3
Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
J Neurooncol. 2014 Jan;116(2):307-13. doi: 10.1007/s11060-013-1293-1. Epub 2013 Oct 29.
4
Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
J Med Genet. 2009 Feb;46(2):81-5. doi: 10.1136/jmg.2008.061051. Epub 2008 Oct 17.
5
Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
Rofo. 2015 Dec;187(12):1084-92. doi: 10.1055/s-0035-1553505. Epub 2015 Sep 2.
7
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24.
8
Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):776-787. doi: 10.1007/s00259-018-4227-5. Epub 2018 Dec 8.

引用本文的文献

1
Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene.
Int J Dev Neurosci. 2025 Oct;85(6):e70049. doi: 10.1002/jdn.70049.
2
Surgical Management of a Giant Mediastinal Schwannoma Associated with Neurofibromatosis Type 1: A Case Report.
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0150. Epub 2025 Aug 22.
5
Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.
Neurooncol Adv. 2025 Feb 16;7(1):vdaf040. doi: 10.1093/noajnl/vdaf040. eCollection 2025 Jan-Dec.
9
[Application of multimodal intraoperative neurophysiological monitoring technology in neurofibromatosis type 1 related peripheral nerve tumor surgery].
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 Oct 15;38(10):1202-1207. doi: 10.7507/1002-1892.202406065.
10
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.
Front Oncol. 2024 Aug 27;14:1323176. doi: 10.3389/fonc.2024.1323176. eCollection 2024.

本文引用的文献

1
[Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1].
Ann Dermatol Venereol. 2007 Oct;134(10 Pt 1):735-41. doi: 10.1016/s0151-9638(07)92528-4.
3
Value of PET in the assessment of patients with neurofibromatosis type 1.
AJR Am J Roentgenol. 2007 Oct;189(4):928-35. doi: 10.2214/AJR.07.2060.
6
Malignant peripheral nerve sheath tumors.
Neurosurg Focus. 2007 Jun 15;22(6):E12. doi: 10.3171/foc.2007.22.6.13.
7
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.
Lancet Neurol. 2007 Apr;6(4):340-51. doi: 10.1016/S1474-4422(07)70075-3.
8
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
Neurology. 2007 Feb 27;68(9):643-7. doi: 10.1212/01.wnl.0000250332.89420.e6. Epub 2007 Jan 10.
9
Clinical manifestations and management of neurofibromatosis type 1.
Semin Pediatr Neurol. 2006 Mar;13(1):2-7. doi: 10.1016/j.spen.2006.01.005.
10
A prospective study of neurofibromatosis type 1 cancer incidence in the UK.
Br J Cancer. 2006 Jul 17;95(2):233-8. doi: 10.1038/sj.bjc.6603227. Epub 2006 Jun 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验